 SAN DIEGO and REDWOOD CITY, Calif., Oct. 31, 2022 GLOBE NEWSWIRE -- eFFECTOR Therapeutics, Inc. NASDAQ: EFTR, a leader in the development of selective translation regulator inhibitors STRIs for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences: 